Treatment of dementia with lewy bodies and Parkinson's disease dementia
Identifieur interne :
000F48 ( PascalFrancis/Curation );
précédent :
000F47;
suivant :
000F49
Treatment of dementia with lewy bodies and Parkinson's disease dementia
Auteurs : Werner Poewe [
Autriche]
Source :
-
Movement disorders [ 0885-3185 ] ; 2005.
RBID : Pascal:05-0457542
Descripteurs français
English descriptors
Abstract
Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD-dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug-induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add-on treatment with atypical neuroleptics to control drug-induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data.
| pA |
| A01 | 01 | 1 | | @0 0885-3185 |
|---|
| A03 | | 1 | | @0 Mov. disord. |
|---|
| A05 | | | | @2 20 |
|---|
| A06 | | | | @3 SUP12 |
|---|
| A08 | 01 | 1 | ENG | @1 Treatment of dementia with lewy bodies and Parkinson's disease dementia |
|---|
| A09 | 01 | 1 | ENG | @1 Atypical Parkinsonian Disorders |
|---|
| A11 | 01 | 1 | | @1 POEWE (Werner) |
|---|
| A12 | 01 | 1 | | @1 POEWE (Werner) @9 ed. |
|---|
| A12 | 02 | 1 | | @1 WENNING (Gregor K.) @9 ed. |
|---|
| A14 | 01 | | | @1 Department of Neurology, Medical University of Innsbruck @3 AUT @Z 1 aut. |
|---|
| A15 | 01 | | | @1 Department of Neurology, Medical University Innsbruck @2 Innsbruck @3 AUT @Z 1 aut. @Z 2 aut. |
|---|
| A20 | | | | @2 S77-S82 |
|---|
| A21 | | | | @1 2005 |
|---|
| A23 | 01 | | | @0 ENG |
|---|
| A43 | 01 | | | @1 INIST @2 20953 @5 354000132714250120 |
|---|
| A44 | | | | @0 0000 @1 © 2005 INIST-CNRS. All rights reserved. |
|---|
| A45 | | | | @0 58 ref. |
|---|
| A47 | 01 | 1 | | @0 05-0457542 |
|---|
| A60 | | | | @1 P @2 C |
|---|
| A61 | | | | @0 A |
|---|
| A64 | 01 | 1 | | @0 Movement disorders |
|---|
| A66 | 01 | | | @0 USA |
|---|
| C01 | 01 | | ENG | @0 Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD-dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug-induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add-on treatment with atypical neuroleptics to control drug-induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data. |
|---|
| C02 | 01 | X | | @0 002B17 |
|---|
| C02 | 02 | X | | @0 002B17G |
|---|
| C02 | 03 | X | | @0 002B17A02 |
|---|
| C03 | 01 | X | FRE | @0 Système nerveux pathologie @5 01 |
|---|
| C03 | 01 | X | ENG | @0 Nervous system diseases @5 01 |
|---|
| C03 | 01 | X | SPA | @0 Sistema nervioso patología @5 01 |
|---|
| C03 | 02 | X | FRE | @0 Parkinson maladie @5 02 |
|---|
| C03 | 02 | X | ENG | @0 Parkinson disease @5 02 |
|---|
| C03 | 02 | X | SPA | @0 Parkinson enfermedad @5 02 |
|---|
| C03 | 03 | X | FRE | @0 Traitement @5 09 |
|---|
| C03 | 03 | X | ENG | @0 Treatment @5 09 |
|---|
| C03 | 03 | X | SPA | @0 Tratamiento @5 09 |
|---|
| C03 | 04 | X | FRE | @0 Démence corps Lewy @2 NM @5 10 |
|---|
| C03 | 04 | X | ENG | @0 Lewy body dementia @2 NM @5 10 |
|---|
| C03 | 04 | X | SPA | @0 Demencia cuerpos Lewy @2 NM @5 10 |
|---|
| C03 | 05 | X | FRE | @0 Cholinesterase @2 FE @5 11 |
|---|
| C03 | 05 | X | ENG | @0 Cholinesterase @2 FE @5 11 |
|---|
| C03 | 05 | X | SPA | @0 Cholinesterase @2 FE @5 11 |
|---|
| C03 | 06 | X | FRE | @0 Antipsychotique @5 12 |
|---|
| C03 | 06 | X | ENG | @0 Antipsychotic @5 12 |
|---|
| C03 | 06 | X | SPA | @0 Antipsicótico @5 12 |
|---|
| C07 | 01 | X | FRE | @0 Carboxylic ester hydrolases @2 FE |
|---|
| C07 | 01 | X | ENG | @0 Carboxylic ester hydrolases @2 FE |
|---|
| C07 | 01 | X | SPA | @0 Carboxylic ester hydrolases @2 FE |
|---|
| C07 | 02 | X | FRE | @0 Esterases @2 FE |
|---|
| C07 | 02 | X | ENG | @0 Esterases @2 FE |
|---|
| C07 | 02 | X | SPA | @0 Esterases @2 FE |
|---|
| C07 | 03 | X | FRE | @0 Hydrolases @2 FE |
|---|
| C07 | 03 | X | ENG | @0 Hydrolases @2 FE |
|---|
| C07 | 03 | X | SPA | @0 Hydrolases @2 FE |
|---|
| C07 | 04 | X | FRE | @0 Enzyme @2 FE |
|---|
| C07 | 04 | X | ENG | @0 Enzyme @2 FE |
|---|
| C07 | 04 | X | SPA | @0 Enzima @2 FE |
|---|
| C07 | 05 | X | FRE | @0 Encéphale pathologie @5 37 |
|---|
| C07 | 05 | X | ENG | @0 Cerebral disorder @5 37 |
|---|
| C07 | 05 | X | SPA | @0 Encéfalo patología @5 37 |
|---|
| C07 | 06 | X | FRE | @0 Extrapyramidal syndrome @5 38 |
|---|
| C07 | 06 | X | ENG | @0 Extrapyramidal syndrome @5 38 |
|---|
| C07 | 06 | X | SPA | @0 Extrapiramidal síndrome @5 38 |
|---|
| C07 | 07 | X | FRE | @0 Maladie dégénérative @5 39 |
|---|
| C07 | 07 | X | ENG | @0 Degenerative disease @5 39 |
|---|
| C07 | 07 | X | SPA | @0 Enfermedad degenerativa @5 39 |
|---|
| C07 | 08 | X | FRE | @0 Système nerveux central pathologie @5 40 |
|---|
| C07 | 08 | X | ENG | @0 Central nervous system disease @5 40 |
|---|
| C07 | 08 | X | SPA | @0 Sistema nervosio central patología @5 40 |
|---|
| N21 | | | | @1 318 |
|---|
| N44 | 01 | | | @1 OTO |
|---|
| N82 | | | | @1 OTO |
|---|
|
|---|
| pR |
| A30 | 01 | 1 | ENG | @1 Atypical Parkinsonian Disorders - From Protein Dysfunction to Therapeutic Intervention. International Meeting @3 Innsbruck AUT @4 2003-02-19 |
|---|
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001D73
Links to Exploration step
Pascal:05-0457542
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Treatment of dementia with lewy bodies and Parkinson's disease dementia</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Medical University of Innsbruck</s1>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</inist:fA14><country>Autriche</country>
</affiliation><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0457542</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0457542 INIST</idno>
<idno type="RBID">Pascal:05-0457542</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001D73</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000F48</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Treatment of dementia with lewy bodies and Parkinson's disease dementia</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Medical University of Innsbruck</s1>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</inist:fA14><country>Autriche</country>
</affiliation><series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint><seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antipsychotic</term>
<term>Cholinesterase</term>
<term>Lewy body dementia</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Traitement</term>
<term>Démence corps Lewy</term>
<term>Cholinesterase</term>
<term>Antipsychotique</term>
</keywords><front><div type="abstract" xml:lang="en">Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD-dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug-induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add-on treatment with atypical neuroleptics to control drug-induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data.</div>
</front><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01><fA03 i2="1"><s0>Mov. disord.</s0>
</fA03><fA06><s3>SUP12</s3>
</fA06><fA08 i1="01" i2="1" l="ENG"><s1>Treatment of dementia with lewy bodies and Parkinson's disease dementia</s1>
</fA08><fA09 i1="01" i2="1" l="ENG"><s1>Atypical Parkinsonian Disorders</s1>
</fA09><fA11 i1="01" i2="1"><s1>POEWE (Werner)</s1>
</fA11><fA12 i1="01" i2="1"><s1>POEWE (Werner)</s1>
<s9>ed.</s9>
</fA12><fA12 i1="02" i2="1"><s1>WENNING (Gregor K.)</s1>
<s9>ed.</s9>
</fA12><fA14 i1="01"><s1>Department of Neurology, Medical University of Innsbruck</s1>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</fA14><fA15 i1="01"><s1>Department of Neurology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA15><fA20><s2>S77-S82</s2>
</fA20><fA21><s1>2005</s1>
</fA21><fA23 i1="01"><s0>ENG</s0>
</fA23><fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000132714250120</s5>
</fA43><fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44><fA45><s0>58 ref.</s0>
</fA45><fA47 i1="01" i2="1"><s0>05-0457542</s0>
</fA47><fA60><s1>P</s1>
<s2>C</s2>
</fA60><fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64><fA66 i1="01"><s0>USA</s0>
</fA66><fC01 i1="01" l="ENG"><s0>Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD-dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug-induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add-on treatment with atypical neuroleptics to control drug-induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data.</s0>
</fC01><fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02><fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02><fC02 i1="03" i2="X"><s0>002B17A02</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03><fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03><fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0>
<s5>09</s5>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0>
<s5>09</s5>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>09</s5>
</fC03><fC03 i1="04" i2="X" l="FRE"><s0>Démence corps Lewy</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03><fC03 i1="04" i2="X" l="ENG"><s0>Lewy body dementia</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03><fC03 i1="04" i2="X" l="SPA"><s0>Demencia cuerpos Lewy</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03><fC03 i1="05" i2="X" l="FRE"><s0>Cholinesterase</s0>
<s2>FE</s2>
<s5>11</s5>
</fC03><fC03 i1="05" i2="X" l="ENG"><s0>Cholinesterase</s0>
<s2>FE</s2>
<s5>11</s5>
</fC03><fC03 i1="05" i2="X" l="SPA"><s0>Cholinesterase</s0>
<s2>FE</s2>
<s5>11</s5>
</fC03><fC03 i1="06" i2="X" l="FRE"><s0>Antipsychotique</s0>
<s5>12</s5>
</fC03><fC03 i1="06" i2="X" l="ENG"><s0>Antipsychotic</s0>
<s5>12</s5>
</fC03><fC03 i1="06" i2="X" l="SPA"><s0>Antipsicótico</s0>
<s5>12</s5>
</fC03><fC07 i1="01" i2="X" l="FRE"><s0>Carboxylic ester hydrolases</s0>
<s2>FE</s2>
</fC07><fC07 i1="01" i2="X" l="ENG"><s0>Carboxylic ester hydrolases</s0>
<s2>FE</s2>
</fC07><fC07 i1="01" i2="X" l="SPA"><s0>Carboxylic ester hydrolases</s0>
<s2>FE</s2>
</fC07><fC07 i1="02" i2="X" l="FRE"><s0>Esterases</s0>
<s2>FE</s2>
</fC07><fC07 i1="02" i2="X" l="ENG"><s0>Esterases</s0>
<s2>FE</s2>
</fC07><fC07 i1="02" i2="X" l="SPA"><s0>Esterases</s0>
<s2>FE</s2>
</fC07><fC07 i1="03" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07><fC07 i1="03" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07><fC07 i1="03" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07><fC07 i1="04" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07><fC07 i1="04" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07><fC07 i1="04" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07><fC07 i1="05" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07><fC07 i1="05" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07><fC07 i1="05" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07><fC07 i1="06" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07><fC07 i1="06" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07><fC07 i1="06" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07><fC07 i1="07" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07><fC07 i1="07" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07><fC07 i1="07" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07><fC07 i1="08" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07><fC07 i1="08" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07><fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07><fN21><s1>318</s1>
</fN21><fN44 i1="01"><s1>OTO</s1>
</fN44><fN82><s1>OTO</s1>
</fN82><pR><fA30 i1="01" i2="1" l="ENG"><s1>Atypical Parkinsonian Disorders - From Protein Dysfunction to Therapeutic Intervention. International Meeting</s1>
<s3>Innsbruck AUT</s3>
<s4>2003-02-19</s4>
</fA30>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000F48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:05-0457542
|texte= Treatment of dementia with lewy bodies and Parkinson's disease dementia
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 |  |
